Mallinckrodt and Novoteris receive clearance from Health Canada to start a pilot trial of high-dose inhaled nitric oxide therapy for COVID-19 infection and associated complications.- Mallinckrodt + Novoteris LLC
Related news and insights
Ad26.COV2-S [recombinant] a single-dose coronavirus vaccine from Janssen, part of Johnson & Johnson, has been approved by the MHRA (UK) and is indicated for active immunisation to prevent COVID-19 caused by SARS-CoV-2 in individuals 18 years of age and older.
Sanofi and GlaxoSmithKline plc (GSK) started enrolment in their Phase III clinical study to assess the safety, efficacy and immunogenicity of their adjuvanted recombinant-protein COVID-19 vaccine candidate.
Moderna, Inc. announced that the Phase II/III study of its COVID-19 vaccine (mRNA-1273) in adolescents has met its primary immunogenicity endpoint, successfully bridging immune responses to the adult vaccination.